A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
Launched by SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. · Mar 21, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written informed consent
- • 2. Body mass index (BMI) ≥18 kg/m2 and ≤28 kg/m2.
- • 3. ASA I - II
- • 4. Experiences a pain intensity rating of moderate to severe acute pain following abdominal surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery
- Exclusion Criteria:
- • 1. Allergy to opioids and other medications that may be used during the trial.
- • 2. Nervous system disorders (e.g. epilepsy)
- • 3. Psychiatric disorders (e.g. depression)
- • 4. History of difficult airways
- • 5. Random blood glucose ≥11.1 mmol/L
- • 6. Uncontrolled blood pressure \[e.g., hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg),or hypotension(systolic blood pressure \<90 mmHg)\]
- • 7. Abnormal pulse oxygen saturation (SpO2 \<90 %)
- • 8. Abnormal liver function or renal function
- • 9. Used agents that could affect the analgesic response
- • 10. Used agents that could affect drug metabolism
- • 11. Has previously participated in another YZJ-4729 clinical study
About Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. is a leading biopharmaceutical company based in Shanghai, specializing in the research, development, and commercialization of innovative therapeutic solutions. With a commitment to advancing healthcare, the company focuses on a diverse range of therapeutic areas, including oncology, neurology, and infectious diseases. Leveraging cutting-edge technology and a robust pipeline of clinical trials, Shanghai Haiyan Pharmaceutical aims to deliver high-quality, effective treatments that address unmet medical needs while adhering to stringent regulatory standards. Through strategic collaborations and a dedication to scientific excellence, the company is positioned to make significant contributions to the global pharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, , China
Chongqing, , China
Chongqing, , China
Changsha, , China
Tianjin, , China
Wuhan, , China
Chengdu, , China
Xiamen, , China
Dongguan, , China
Zhuzhou, , China
Nanchang, , China
Guangzhou, , China
Xi'an, , China
Luoyang, , China
Shanghai, , China
Neijiang, , China
Dalian, , China
Deyang, , China
Cangzhou, , China
Ningbo, , China
Ch'ang Ch'un, , China
Jiaxing, , China
Cangzhou, , China
Hengyang, , China
Huzhou, , China
Liuzhou, , China
Guangzhou, , China
Shanghai, , China
Taizhou, , China
Wuxi, , China
Haikou, , China
Mianyang, , China
Wuhan, , China
Chengdu, , China
Guangzhou, , China
Ganzhou, , China
Ha'erbin, , China
Ma'anshan, , China
Changsha, , China
Yibin, , China
Changsha, , China
Changde, , China
Liuzhou, , China
Chengdu, , China
Guangyuan, , China
Hefei, , China
Nanning, , China
Qingdao, , China
Zhangzhou, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported